108 related articles for article (PubMed ID: 6529476)
1. Experimental and clinical results with the Corynebacterium granulosum-derived immunomodulator P40.
Bizzini B; Henocq E; Reynier J; Relyveld EH
Asian Pac J Allergy Immunol; 1984 Jun; 2(1):144-53. PubMed ID: 6529476
[No Abstract] [Full Text] [Related]
2. Induction of various cytokines in mice and activation of the complement system in rats as a part of the mechanism of action of the Corynebacterium granulosum-derived P40 immunomodulator.
Bizzini B; Carlotti M; Fattal-German M
FEMS Microbiol Immunol; 1992 Oct; 5(4):171-80. PubMed ID: 1384603
[TBL] [Abstract][Full Text] [Related]
3. The Corynebacterium granulosum-derived P40 immunomodulator exerts a synergistic effect on the activity of antiviral drugs in the treatment of experimental viral infections.
Fattal-German M; Bizzini B
Biomed Pharmacother; 1988; 42(3):217-20. PubMed ID: 3179407
[TBL] [Abstract][Full Text] [Related]
4. The restoration of impaired macrophage functions using as immunomodulator the Corynebacterium granulosum-derived P40 fraction.
Mastroeni P; Bizzini B; Bonina L; Iannello D; Merendino RA; Delfino D; Berlinghieri MC; Leonardi MS; Arena A; Liberto MC
Immunopharmacology; 1985 Aug; 10(1):27-34. PubMed ID: 2997082
[TBL] [Abstract][Full Text] [Related]
5. Potentiating the effectiveness of influenza vaccination by a combined immunostimulation with P40 immunomodulator: an experimental study in mice.
Fattal-German M; German A; Bizzini B
Biomed Pharmacother; 1988; 42(1):73-8. PubMed ID: 3408809
[TBL] [Abstract][Full Text] [Related]
6. Anti-infectious effect of C granulosum-derived P40 immunomodulator given by aerosolization and intranasal instillation.
Bizzini B; Carlotti M; Fattal German M
Biomed Pharmacother; 1992; 46(10):491-4. PubMed ID: 1306363
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experimental and clinical results with inactivated allergens conjugated to the Corynebacterium granulosum-derived immunomodulator P40.
Henocq E; Prouvost-Danon A; Bizzini B
Boll Ist Sieroter Milan; 1987; 66(1):70-7. PubMed ID: 3620123
[TBL] [Abstract][Full Text] [Related]
8. [Effect of an immunomodulator (P40) on Escherichia coli urinary infection in the rat].
Mathieu D; Fries D; Auer J; Bizzini B; Jacques L
Biomed Pharmacother; 1982; 36(10):420-5. PubMed ID: 6764138
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation with P40, an insoluble delipidated fraction of Corynebacterium granulosum. II.--Specific immune responses of the host.
Lagrange PH; Fuster MJ
Ann Immunol (Paris); 1982; 133C(3):269-87. PubMed ID: 7149643
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of L1210 mouse leukemia by immunization with xenogenized tumor cells combined with immunostimulation by the P40 fraction of C. granulosum and chemotherapy.
Relyveld EH; Bizzini B; Ben-Efraim S
Int J Immunopharmacol; 1984; 6(5):445-50. PubMed ID: 6500782
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and therapy of L1210 leukemia in mice, using inactivated and grafted tumor cells, in association with the immunomodulator P40, and Antineoplastic Agents (author's transl)].
Relyveld EH; Bizzini B; Ben-Efraim S
C R Seances Acad Sci III; 1982 Mar; 294(12):571-6. PubMed ID: 6809234
[TBL] [Abstract][Full Text] [Related]
12. E. coli infections of the lower urinary tract and their treatment by immunomodulation or combined immunomodulation and antigen therapy.
Mathieu D; Jacques L; Auer J; Bizzini B
Biomed Pharmacother; 1988; 42(4):271-7. PubMed ID: 3056533
[TBL] [Abstract][Full Text] [Related]
13. [Protective effect of P40 fraction of C. granulosum against leukemia L1210 in mice].
Relyveld EH; Bizzini B; Ben-Efraim S
C R Seances Acad Sci III; 1981 Jul; 293(1):39-42. PubMed ID: 6796201
[TBL] [Abstract][Full Text] [Related]
14. Potentiation by nonspecific immunostimulation of the efficacy of antibiotics in the treatment of experimental bacterial infections.
Bizzini B; Fattal-German M
Biomed Pharmacother; 1989; 43(10):753-61. PubMed ID: 2534887
[TBL] [Abstract][Full Text] [Related]
15. Immunological investigation and immunotherapy in patients operated on for breast carcinoma.
Reynier J; Villet R; Bazin JC; Bizzini B; Gandrille C; Guettier C; Henocq E; Hollmann K; Mogenet M; Pompidou A; Santus JP; Verley JM
Int Surg; 1982; 67(1):17-24. PubMed ID: 7095998
[TBL] [Abstract][Full Text] [Related]
16. [Corynebacteria--stimulators of antitumor resistance].
Zatula DG; Zaval'niuk AK; Tofan AV
Eksp Onkol; 1984; 6(6):12-8. PubMed ID: 6396064
[TBL] [Abstract][Full Text] [Related]
17. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
[No Abstract] [Full Text] [Related]
18. [Effect of anaerobic Corynebacterium on immunologic response of mice].
Nagoya T; Yoshimura Y; Saino H; Eda J; Kobayashi T
Nihon Saikingaku Zasshi; 1975 Jan; 30(1):215. PubMed ID: 1240247
[No Abstract] [Full Text] [Related]
19. Evaluation of Corynebacterium granulosum derived P40 fraction effects on macrophage anti-herpes simplex virus type 1 functions.
Iannello D; Bonina L; Merendino RA; Arena A; Mastroeni P; Bizzini B
Antiviral Res; 1985; Suppl 1():167-71. PubMed ID: 2417550
[No Abstract] [Full Text] [Related]
20. Nonspecific immunotherapy of malignant tumors.
Milas L; Withers HR
Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
